Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.

Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR.

J Med Chem. 2018 Feb 8;61(3):934-945. doi: 10.1021/acs.jmedchem.7b01411. Epub 2018 Jan 5.

PMID:
29236497
2.

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).

Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, Wilbur KL, Lineswala JP, Piper JL, Coffey DS, Sweetana SA, Haas JV, Brooks DA, Pratt EJ, Belin RM, Deeg MA, Ma X, Cannady EA, Johnson JT, Yumibe NP, Chen Q, Maiti P, Montrose-Rafizadeh C, Chen Y, Reifel Miller A.

J Med Chem. 2016 Dec 22;59(24):10891-10916. doi: 10.1021/acs.jmedchem.6b00892. Epub 2016 Nov 11.

PMID:
27749056
3.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.

Zhou X, Rougée LR, Bedwell DW, Cramer JW, Mohutsky MA, Calvert NA, Moulton RD, Cassidy KC, Yumibe NP, Adams LA, Ruterbories KJ.

Drug Metab Dispos. 2016 Aug;44(8):1184-92. doi: 10.1124/dmd.116.070623. Epub 2016 May 23.

PMID:
27217490
4.

Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers.

Pritt ML, Hall DG, Recknor J, Credille KM, Brown DD, Yumibe NP, Schultze AE, Watson DE.

Toxicol Sci. 2008 Jun;103(2):382-96. doi: 10.1093/toxsci/kfn042. Epub 2008 Feb 27.

PMID:
18308699
5.

Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.

Shi Q, Canada EJ, Xu Y, Warshawsky AM, Etgen GJ, Broderick CL, Clutinger CK, Irwin LA, Laurila ME, Montrose-Rafizadeh C, Oldham BA, Wang M, Winneroski LL, Xie C, York JS, Yumibe NP, Zink RW, Mantlo N.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6744-9. Epub 2007 Oct 18.

PMID:
18029178
6.

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6293-7. Epub 2006 Sep 26.

PMID:
17005393
7.

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.

Xu Y, Mayhugh D, Saeed A, Wang X, Thompson RC, Dominianni SJ, Kauffman RF, Singh J, Bean JS, Bensch WR, Barr RJ, Osborne J, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Huang N, Luffer-Atlas D, Rungta D, Maise DE, Mantlo NB.

J Med Chem. 2003 Nov 20;46(24):5121-4.

PMID:
14613314
8.

The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios.

Lau YY, Krishna G, Yumibe NP, Grotz DE, Sapidou E, Norton L, Chu I, Chen C, Soares AD, Lin CC.

Pharm Res. 2002 Nov;19(11):1606-10.

PMID:
12458665
9.

In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr.

J Pharmacol Exp Ther. 1997 Oct;283(1):157-63.

PMID:
9336320
10.

Mechanistic aspects of cytochrome P-450-hydroperoxide interactions: substituent effects on degradative pathways.

Thompson JA, Yumibe NP.

Drug Metab Rev. 1989;20(2-4):365-78. Review. No abstract available.

PMID:
2680387
11.

Supplemental Content

Loading ...
Support Center